In Vivo Antineoplastic Effects of the NSAID Sulindac in an Oral Carcinogenesis Model.
The antineoplastic properties of the NSAID sulindac have long been studied. The purpose of this study was to explore sulindac's in vivo effects on oral squamous cell carcinoma (SCC) oncogenesis using the hamster cheek pouch oral carcinogenesis model (HOCM). Thirty Syrian golden hamsters were divided into three experimental and two control groups (n = 6 each). The animals' right buccal pouches were treated with carcinogen for 9 weeks in one experimental and one control group and for 14 weeks in all other three groups. The animals of two experimental groups received sulindac from the 1st week and those of the third experimental group from the 10th week. After the end of carcinogenesis, treated buccal pouches were removed and examined. In animals treated with carcinogen for 14 weeks, development of oral SCC and tumor volume were significantly lower in animals that received sulindac from the first week of the experiment. Oral SCC developing in animals that received sulindac were more frequently well differentiated compared with the control group. In animals treated with carcinogen for 9 weeks, the animals that received sulindac developed lower grade of epithelial dysplasia. Proliferation index Ki-67 and positivity for the antiapoptotic molecule survivin were lower in the animals that received sulindac. Treatment with sulindac appears to delays the progression of oral premalignant lesions to oral SCC in the HOCM, also resulting in smaller and better differentiated tumors. These in vivo antineoplastic effects may be related to sulindac's ability to decrease cell proliferation and to prevent survivin expression.
Department of Oral Medicine and Pathology, Dental School, National and Kapodistrian University of Athens, Greece. k_katoumas@hotmail.com.
Konstantinos
K
Katoumas
Department of Oral Medicine and Pathology, Dental School, National and Kapodistrian University of Athens, Greece.
Nikolaos
N
Nikitakis
Laboratory of Experimental Surgery and Surgical Research "N.S. Christeas," School of Medicine, National and Kapodistrian University of Athens, Greece.
Despina
D
Perrea
Laboratory of Experimental Surgery and Surgical Research "N.S. Christeas," School of Medicine, National and Kapodistrian University of Athens, Greece.
Ismene
I
Dontas
Department of Oral Medicine and Pathology, Dental School, National and Kapodistrian University of Athens, Greece.
Alexandra
A
Sklavounou
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D006224:Cricetinae; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D008297:Male; D008647:Mesocricetus; D009062:Mouth Neoplasms / Q000473:pathology*; D013467:Sulindac / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D013467:Sulindac